Viridian Therapeutics, Inc.\DE (VRDN) Total Non-Current Liabilities (2014 - 2026)

Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $140.5 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 157.23% year-over-year to $140.5 million; the TTM figure through Mar 2026 stood at $140.5 million (up 157.23% YoY), while the FY2025 annual figure was $157.2 million, up 129.67% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $140.5 million, down from $157.2 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $157.2 million in Q4 2025, with the low at $15.5 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $47.4 million (2023), against an average of $58.5 million.
• Peak annual rise in Total Non-Current Liabilities reached 162.8% in 2022, while the deepest fall reached 7.96% in 2022.
• Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities stood at $38.9 million in 2022, then gained by 22.03% to $47.4 million in 2023, then surged by 44.38% to $68.5 million in 2024, then jumped by 129.67% to $157.2 million in 2025, then dropped by 10.63% to $140.5 million in 2026.
• Business Quant data shows VRDN's Total Non-Current Liabilities at $140.5 million in Q1 2026, $157.2 million in Q4 2025, and $71.6 million in Q3 2025.